NP-003 Steady-state pharmacokinetics and early safety data in HIV-infected african children weighing ≥25 kg after switching to 50 mg film-coated dolutegravir tablets in the ODYSSEY trial

Pdj Bollen,P Rojo,S Makumbi,A Turkova,P Amuge,A Parker,A Lugemwa,A Nanduudu,Dm Gibb,E Chidziva,E Kaudha,Dm Burger,S Montero,D Ford,H Mujuru,C Shakeshaft,A Colbers,A Kekitiinwa

doi:10.1136/ejhpharm-2020-eahpconf.461

NP-003 Steady-state pharmacokinetics and early safety data in HIV-infected african children weighing ≥25 kg after switching to 50 mg film-coated dolutegravir tablets in the ODYSSEY trial

Pdj Bollen, P Rojo + Show 16 more

Open Access

https://doi.org/10.1136/ejhpharm-2020-eahpconf.461

Copy DOI

Journal: European Journal of Hospital Pharmacy: Science and Practice

Publication Date: Mar 1, 2020

Affiliation: Radboud University Nijmegen Medical Centre, Radboud University Nijmegen, Research Institute Hospital 12 de Octubre, Joint Clinical Research Centre, University College London, Medical Research Council, Baylor College of Medicine Children’s Foundation, University of Zimbabwe

#Film-coated Tablets #Dolutegravir + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and importanceODYSSEY is an ongoing international randomised trial evaluating dolutegravir (DTG)-based antiretroviral therapy (ART) versus standard-of-care in HIV-infected children starting first- or second-line ART. Pediatric DTG film-coated tablets (FCTs)...

Full Text